Regeneron Pharmaceuticals Inc to Purchase Sanofi's Stake in Libtayo Investor Call Transcript
Welcome to the Regeneron Pharmaceutical Analyst and Investor Conference Call to discuss with Regeneron's intent to acquire global rights to Libtayo. My name is Norma, and I will be the operator for today's conference.
(Operator Instructions)
Please note that today's conference is being recorded. I will now turn the call over to Ryan Crowe, Vice President, Investor Relations. You may begin.
Thank you, Norma. Good morning, good afternoon and good evening to everyone listening around the globe. Thank you for joining us on short notice. Welcome to our investor call to discuss our intent to acquire global rights to Libtayo from Sanofi. An archive of this webcast will be available on our Investor Relations website shortly after the call ends. Joining me today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President and Head of Commercial; and Bob Landry,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |